Citius Oncology, Inc.
CTOR
$0.94
$0.011.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.49M | 1.67M | 3.94M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.49M | 1.67M | 3.94M | -- | -- |
| Cost of Revenue | 671.30K | 328.90K | 789.20K | -- | -- |
| Gross Profit | 822.50K | 1.34M | 3.15M | -- | -- |
| SG&A Expenses | 7.78M | 27.15M | 6.82M | 3.64M | 4.01M |
| Depreciation & Amortization | 1.72M | 1.72M | 573.40K | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.39M | 30.28M | 9.20M | 4.71M | 4.95M |
| Operating Income | -8.90M | -28.61M | -5.25M | -4.71M | -4.95M |
| Income Before Tax | -9.03M | -26.84M | -5.27M | -4.73M | -5.11M |
| Income Tax Expenses | -107.30K | -231.20K | 264.20K | 264.20K | 264.20K |
| Earnings from Continuing Operations | -8.92M | -26.61M | -5.53M | -5.00M | -5.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.92M | -26.61M | -5.53M | -5.00M | -5.37M |
| EBIT | -8.90M | -28.61M | -5.25M | -4.71M | -4.95M |
| EBITDA | -7.18M | -26.89M | -4.68M | -- | -- |
| EPS Basic | -0.08 | -0.27 | -0.06 | -0.06 | -0.08 |
| Normalized Basic EPS | -0.05 | -0.17 | -0.04 | -0.04 | -0.04 |
| EPS Diluted | -0.08 | -0.27 | -0.06 | -0.06 | -0.08 |
| Normalized Diluted EPS | -0.05 | -0.17 | -0.04 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 107.89M | 100.03M | 87.46M | 78.41M | 71.55M |
| Average Diluted Shares Outstanding | 107.89M | 100.03M | 87.46M | 78.41M | 71.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |